Jason Rickard - 28 Feb 2022 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
SVP, Chief Operating Officer
Signature
/s/ Brian Tessler, Attorney-in-Fact
Issuer symbol
IRWD
Transactions as of
28 Feb 2022
Net transactions value
-$311,921
Form type
4
Filing time
02 Mar 2022, 15:00:59 UTC
Previous filing
21 Jan 2022
Next filing
04 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Sale $20,603 -1,913 -0.54% $10.77 354,162 28 Feb 2022 Direct F1
transaction IRWD Class A Common Stock Sale $33,926 -3,150 -0.89% $10.77 351,012 28 Feb 2022 Direct F2
transaction IRWD Class A Common Stock Sale $64,857 -6,022 -1.7% $10.77 344,990 28 Feb 2022 Direct F3
transaction IRWD Class A Common Stock Sale $119,084 -11,057 -3.2% $10.77 333,933 28 Feb 2022 Direct F4
transaction IRWD Class A Common Stock Sale $73,451 -6,820 -2% $10.77 327,113 28 Feb 2022 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018.
F2 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019.
F3 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020.
F4 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting of the reporting person's performance-based restricted stock units granted on February 27, 2020.
F5 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 22, 2021.